Related Experiment Video
Updated: Aug 19, 2025
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
2018 Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis
Xinping Tian1, Qian Wang1, Mengtao Li1
1Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Chinese Rheumatism Data Center (CRDC), Chinese SLE Treatment and Research Group (CSTAR), Beijing, China.
Insights
This guideline provides evidence-based recommendations for rheumatoid arthritis (RA) diagnosis and treatment in China. It details classification, monitoring, and therapies like DMARDs, biologics, and glucocorticoids for improved RA management.
Area of Science:
- Rheumatology
- Clinical Practice Guidelines
- Evidence-Based Medicine
Background:
- Rheumatoid arthritis (RA) poses a significant health challenge in China.
- Existing RA management strategies require updated, evidence-based guidance.
Purpose of the Study:
- To develop comprehensive, evidence-based guidelines for RA diagnosis and treatment tailored for China.
- To standardize RA care through a multidisciplinary approach.
Main Methods:
- Established a multidisciplinary guideline development group.
- Utilized the GRADE system to assess evidence quality and recommendation strength.
- Synthesized findings from research articles, considering benefits, harms, and patient values.
Main Results:
- Formulated 10 key recommendations for RA diagnosis and treatment.
- Guidelines cover classification criteria, disease activity assessment, and monitoring.
- Recommendations address the role of DMARDs, biologics, small molecule drugs, and glucocorticoids within a treat-to-target strategy.
Conclusions:
- The guideline offers a structured approach to RA management in China.
- Aims to enhance clinical decision-making and patient care practices for RA.
- Promotes the optimal use of available therapies for rheumatoid arthritis.
Abstract:
A multidisciplinary guideline development group was established to formulate this evidence-based diagnosis and treatment guidelines for rheumatoid arthritis (RA) in China. The grading of recommendations, assessment, development, and evaluation (GRADE) system was used to rate the quality of the evidence and the strength of recommendations, which were derived from research articles and guided by the analysis of the benefits and harms as well as patients' values and preferences. A total of 10 recommendations for the diagnosis and treatment of RA were developed. This new guideline covered the classification criteria, disease activity assessment and monitoring, and the role of disease modifying antirheumatic drugs (DMARDs), biologics, small molecule synthetic targeting drugs, and glucocorticoids in the treat-to-target approach of RA. This guideline is intended to serve as a tool for clinicians and patients to implement decision-making strategies and improve the practices of RA management in China.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:20Rheumatic Heart Disease IV: Nursing Management
01:23Rheumatic Heart Disease I: Introduction
01:22Connective Tissue Cell Types
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...